Nothing Special   »   [go: up one dir, main page]

HUP0400115A2 - Pharmaceutical composition for the intramuscular administration of fulvestrant - Google Patents

Pharmaceutical composition for the intramuscular administration of fulvestrant

Info

Publication number
HUP0400115A2
HUP0400115A2 HU0400115A HUP0400115A HUP0400115A2 HU P0400115 A2 HUP0400115 A2 HU P0400115A2 HU 0400115 A HU0400115 A HU 0400115A HU P0400115 A HUP0400115 A HU P0400115A HU P0400115 A2 HUP0400115 A2 HU P0400115A2
Authority
HU
Hungary
Prior art keywords
fulvestrant
pharmaceutical composition
intramuscular administration
weight
medically usable
Prior art date
Application number
HU0400115A
Other languages
Hungarian (hu)
Inventor
Julie Kay Cahill
Paul Richard Gellert
Alan Marshall Irving
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0400115A2 publication Critical patent/HUP0400115A2/en
Publication of HUP0400115A3 publication Critical patent/HUP0400115A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány tárgya intramuszkuláris injekció formájában beadhatógyógyászati készítmény, ami legalább 100 mg/ml fulvesztrantot, akészítmény hordozóanyagának térfogatára vonatkoztatva legalább 10tömeg% gyógyászatilag alkalmazható alkoholt, legalább 5 tömeg%gyógyászatilag alkalmazható nemvizes észter oldószert és legalább 5tömeg% ricinoleát excipienst tartatmaz. ÓThe subject of the invention is a medicinal preparation that can be administered in the form of an intramuscular injection, which contains at least 100 mg/ml of fulvestrant, at least 10% by weight of medically usable alcohol, at least 5% by weight of medically usable non-aqueous ester solvent and at least 5% by weight of the excipient ricinoleate. HE

HU0400115A 2001-07-07 2002-07-03 Pharmaceutical composition for the intramuscular administration of fulvestrant HUP0400115A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30
PCT/GB2002/003092 WO2003006064A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Publications (2)

Publication Number Publication Date
HUP0400115A2 true HUP0400115A2 (en) 2004-06-28
HUP0400115A3 HUP0400115A3 (en) 2005-11-28

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400115A HUP0400115A3 (en) 2001-07-07 2002-07-03 Pharmaceutical composition for the intramuscular administration of fulvestrant

Country Status (15)

Country Link
EP (1) EP1406662A1 (en)
JP (1) JP2004534093A (en)
CN (1) CN1553815A (en)
AR (1) AR037138A1 (en)
BR (1) BR0210898A (en)
CA (1) CA2453111A1 (en)
CO (1) CO5560585A2 (en)
HU (1) HUP0400115A3 (en)
IL (1) IL159576A0 (en)
IS (1) IS7097A (en)
MX (1) MXPA04000028A (en)
NO (1) NO20040047L (en)
PL (1) PL367624A1 (en)
RU (1) RU2004102393A (en)
WO (1) WO2003006064A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
WO2011022861A1 (en) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600065B (en) * 2012-03-31 2014-08-13 莱普德制药有限公司 Fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
CN102600064A (en) * 2012-03-31 2012-07-25 西安力邦制药有限公司 Fulvestrant or fulvestrant derivative sustained release preparation and preparation method thereof
CN102600073B (en) * 2012-03-31 2014-01-01 莱普德制药有限公司 Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method of oily preparation
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2017175810A1 (en) * 2016-04-06 2017-10-12 富士フイルム株式会社 Medicinal composition
MX2018013414A (en) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use.
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
EP3466430B1 (en) 2016-05-31 2020-04-29 FUJIFILM Corporation Pharmaceutical composition
MA50570A (en) * 2017-11-08 2020-09-16 Eagle Pharmaceuticals Inc FULVESTRANT FORMULATIONS AND METHODS OF USING THE LATTER
WO2019113361A1 (en) * 2017-12-07 2019-06-13 Nevakar Inc. Concentrated fulvestrant compositions
CN111465398A (en) * 2018-01-31 2020-07-28 富士胶片株式会社 Method for producing injection preparation
CN111481559B (en) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 High-concentration fulvestrant composition and preparation method thereof
CN113260353A (en) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 Fulvestrant pharmaceutical composition, preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
NO20040047L (en) 2004-02-23
IS7097A (en) 2004-01-05
HUP0400115A3 (en) 2005-11-28
BR0210898A (en) 2004-06-22
IL159576A0 (en) 2004-06-01
CA2453111A1 (en) 2003-01-23
EP1406662A1 (en) 2004-04-14
WO2003006064A1 (en) 2003-01-23
RU2004102393A (en) 2005-03-27
CN1553815A (en) 2004-12-08
AR037138A1 (en) 2004-10-27
JP2004534093A (en) 2004-11-11
MXPA04000028A (en) 2004-05-21
CO5560585A2 (en) 2005-09-30
PL367624A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
HUP0400115A2 (en) Pharmaceutical composition for the intramuscular administration of fulvestrant
HUP0204137A2 (en) Pharmaceutical composition comprising fulvestrant
HUP0302319A2 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
WO2002043765A3 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2001087284A3 (en) Aldosterone antagonist composition for release during aldosterone acrophase
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
CY1115484T1 (en) UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND CONCLUSIONS, AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND DISEASE
WO2002015903A3 (en) Novel pharmaceutical composition for administering n-0923
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ID29181A (en) COMBINATION OF FORMOTEROL AND TIOTROPIUM SALT
EP0693924A4 (en) METHODS FOR -i(IN VIVO) DELIVERY OF BIOLOGICS AND COMPOSITIONS USEFUL THEREFOR
ATE204160T1 (en) FORMULATION FOR INHALATION APPLICATION
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
ATE298324T1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
SE0102036D0 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
ATE358477T1 (en) ORAL MEDICINAL COMPOSITION CONTAINING A STATIN DERIVATIVE
HUP0301390A2 (en) Oral pharmaceutical composition containing valsartan
ITRM20010226A0 (en) REDUCED HEIGHT IMPLANTABLE DEVICE FOR THE ADMINISTRATION OF MEDICINAL PREPARATIONS.
MY129450A (en) Pharmaceutical composition
MXPA06000332A (en) Novel solid pharmaceutical composition comprising amisulpride.
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
UA93365C2 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts, and processes for the preparation thereof
BRPI0407438A (en) Therapeutic system comprising amoxicillin and clavulanic acid
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
DE60036199D1 (en) PROTEASERESISTENT FLINT ANALOG